Gilead Sciences Inc. (GILD)
GILD trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/882095/000088209526000006/0000882095-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GILD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1992 |
| SEC CIK | 0000882095 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $29.4B |
| Net income | $8.5B |
| Operating income | $10.0B |
| Net margin | 28.9% |
| Operating margin | 34.0% |
| Revenue growth | +2.4% |
| Cash | $7.6B |
| Total assets | $59.0B |
| P/E (computed) | 24.4× |
| P/S (computed) | 7.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-30 |
| Cash and burn | $6.4B cash; operating cash flow $3.6B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,240,338,614 (2026-10-23); 1,240,679,623 a year earlier; 1,246,041,895 three years earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-05-18 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $83.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $8.3B | $2.4B | $5.0B | $6.4B | $26.2B | $31.0B | 10-Q 2026-10-30 |
| Q2 2026 2026-06-30 | $7.8B | -$10.5B | $3.6B | $3.2B | $26.2B | $30.5B | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $7.0B | $2.0B | $2.5B | $7.6B | $22.2B | $29.7B | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $7.9B | $2.2B | $3.3B | $7.6B | $24.9B | $29.4B | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $7.8B | $3.1B | $4.1B | $7.3B | $24.9B | $29.1B | 10-Q 2026-10-30 |
| Q2 2025 2025-06-30 | $7.1B | $2.0B | $827.0M | $5.1B | $24.9B | $28.9B | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $6.7B | $1.3B | $1.8B | $7.9B | $25.0B | $28.7B | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $7.6B | $1.8B | $3.0B | $10.0B | $26.7B | $28.8B | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-08-06 |
| Latest annual report FORM 10-K | 10-K | 2026-02-24 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-10-30 |
| Latest current report FORM 8-K | 8-K | 2026-10-29 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-20 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.7% |
| 1 month | +13.6% |
| 3 months | +21.7% |
| Year to date | +36.9% |
| 1 year | +34.2% |
| From 52-week high | -3.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMGN | Amgen Inc. | $462.32 | -0.72% | $250.1B |
| MRNA | Moderna Inc. | $215.27 | -3.63% | $87.1B |
| ARGX | argenx SE | $950.95 | -0.95% | $59.0B |
| BIIB | Biogen Inc. | $251.65 | -0.69% | $37.2B |
| RVMD | Revolution Medicines Inc. | $166.87 | -3.15% | $36.1B |
| BNTX | BioNTech SE American Depositary Share | $85.26 | -0.40% | $21.4B |
| NBIX | Neurocrine Biosciences Inc. | $165.31 | -1.25% | $16.7B |
| EXEL | Exelixis Inc. | $67.10 | -2.75% | $16.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier